MoonLake Immunotherapeutics has unveiled encouraging long-term outcomes for its primary therapeutic agent, sonelokimab, in patients afflicted with hidradenitis suppurativa (HS). The latest data indicates a sustained and robust response, paving the way for potential regulatory submission to the U.S. Food and Drug Administration (FDA). These developments underscore the drug's promise in addressing this chronic inflammatory skin condition and improving patients' lives.
Hidradenitis suppurativa is a persistent, non-contagious inflammatory skin disorder, also known as acne inversa. It manifests as painful, recurrent nodules and abscesses, predominantly in areas rich in sweat glands, such as the armpits and groin. The debilitating nature of HS often significantly impacts patients' physical and emotional well-being.
MoonLake’s recent findings, presented at the 2026 American Academy of Dermatology Annual Meeting, highlight sonelokimab’s significant efficacy. A remarkable 62% of participants treated with sonelokimab achieved a HiSCR75 response by week 40, marking a new benchmark for sustained lesion control in HS. Furthermore, a detailed examination of various hallmark HS lesions revealed that up to 25% of patients experienced complete inflammatory remission by week 40, characterized by a 100% reduction in abscesses (A100), nodules (N100), and draining tunnels (DT100).
Beyond clinical markers, sonelokimab-treated individuals also reported substantial enhancements in their quality of life by week 40 compared to baseline measures. Improvements ranged from 41% for pain relief, 54% for daily activities like walking and dressing, to an impressive 62% reduction in feelings of depression. Up to 43% of patients achieved at least a three-point reduction from baseline in their worst skin pain NRS scores. Crucially, the safety profile of sonelokimab remained consistent throughout the VELA clinical trials, with no new adverse events reported.
Looking ahead, MoonLake anticipates releasing 52-week data from its VELA-1 and VELA-2 trials for HS in the second quarter of 2026. The company received favorable feedback from the FDA in January regarding its clinical evidence strategy for sonelokimab in HS, suggesting that the current data may suffice for establishing substantial evidence of effectiveness without the need for additional clinical trials. The FDA also recommended submitting the VELA-2 trial results for the marketing application to inform the drug's safety profile. MoonLake is currently progressing with its preparations for a Biologics License Application (BLA) submission, slated for the latter half of 2026.
In a separate but equally significant development, MoonLake shared positive top-line results in February from its Phase 2 clinical trial of sonelokimab for axial spondyloarthritis. The S-OLARIS trial demonstrated that 81% of patients receiving sonelokimab achieved a clinically meaningful response by week 12, indicating considerable improvement across key disease parameters. Despite these positive clinical advancements, MoonLake shares experienced a slight downturn, trading at $16.87 at the time of publication.
MoonLake Immunotherapeutics continues to make strides in medical research, with sonelokimab demonstrating sustained efficacy in treating hidradenitis suppurativa and showing promise for axial spondyloarthritis. The company's ongoing dialogue with the FDA and forthcoming data releases suggest a robust path towards bringing this innovative treatment to patients in need, potentially transforming the management of these challenging inflammatory conditions.